Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | AGER | Q15109 | 3/20 | 0.34 |
| ▸ | PDE2A | O00408 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6709851 | 0.90 | RXFP1 (0.39) | LMNAMAPTRXFP1TP53POLB | |
| SCHEMBL6707636 | 0.89 | GPR35 (0.46) | GPR35SMN1; SMN2MAPTHIF1ANPSR1 | |
| SCHEMBL6714035 | 0.89 | ROCK2 (0.36) | AKR1C2AKR1C1LMNAMAPTTP53 | |
| SCHEMBL6713419 | 0.88 | SRD5A2 (0.44) | GPR35SMN1; SMN2LMNAMAPTHIF1A | |
| SCHEMBL6708937 | 0.88 | KDM1A (0.42) | GPR35 | |
| SCHEMBL6713492 | 0.88 | GPR35 (0.37) | GPR35LMNAMAPTHIF1ANPSR1 | |
| SCHEMBL6713361 | 0.87 | KDM1A (0.41) | GPR35 | |
| SCHEMBL6713703 | 0.84 | AKR1C2 (0.40) | AKR1C2AKR1C1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6707879 | 0.84 | RXFP1 (0.37) | LMNAMAPTHIF1ANPSR1RXFP1 | |
| SCHEMBL6711912 | 0.83 | EPHX1 (0.40) | RAB9ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | AKR1C2 2196/4885AKR1C1 1676/4885GPR35 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.